Evolution of the Average Target: Seres Therapeutics, Inc.

Evolution of the Average Target - Seres Therapeutics, Inc.

Evolution of the Target Price: Seres Therapeutics, Inc.

Evolution of the Target Price - Seres Therapeutics, Inc.

Changes in Analyst Recommendations: Seres Therapeutics, Inc.

752983d0630650de48.ER6bqBPExiLGYcH5alEqPYUEpLRqVAaX1tCtMM2AnjM.cifQnWWNrhuSVau-CyFwcLRLztgSA0_x5IScHfrE70d5TcGRa4fxevAgtg~20e14e476176d9fe68aab40099c1a332
23/06 HC Wainwright Initiates Seres Therapeutics at Buy With $12 Price Target MT
09/05/25 Seres Therapeutics Shares Fall After Downgrade From Chardan MT
08/05/25 Chardan Downgrades Seres Therapeutics to Neutral From Buy, Adjusts Price Target to $6 From $25 MT
24/10/24 JPMorgan Downgrades Seres Therapeutics to Underweight MT
07/06/24 Canaccord Genuity Adjusts Price Target on Seres Therapeutics to $10 From $15, Maintains Buy Rating MT
07/06/24 Oppenheimer Downgrades Seres Therapeutics to Perform From Outperform, Removes $4 Price Target MT
07/06/24 Chardan Adjusts PT on Seres Therapeutics to $1.25 From $6 on Heels of Announced MoU With Nestle for Sale of VOWST Assets; Maintains Buy Rating MT
10/05/24 Oppenheimer Adjusts Seres Therapeutics Price Target to $4 From $5, Maintains Outperform Rating MT
09/05/24 Chardan Adjusts Price Target on Seres Therapeutics to $6 From $8, Keeps Buy Rating MT
07/03/24 Oppenheimer Adjusts Seres Therapeutics Price Target to $5 From $9, Maintains Outperform Rating MT
06/03/24 Chardan Cuts Price Target on Seres Therapeutics to $8 From $10 on Higher Expected Sharecount Dilution, Keeps Buy Rating MT
17/01/24 Oppenheimer Trims Seres Therapeutics Price Target to $9 From $10, Maintains Outperform Rating MT
04/11/23 Goldman Sachs Adjusts Price Target on Seres Therapeutics to $1.25 From $4, Maintains Sell Rating MT
04/11/23 Oppenheimer Adjusts Seres Therapeutics Price Target to $10 From $12, Maintains Outperform Rating MT
28/04/23 Chardan Cuts Price Target on Seres Therapeutics to $10 From $12, Keeps Buy Rating MT
21/04/23 JPMorgan Starts Seres Therapeutics at Neutral MT
22/03/23 Canaccord Genuity Adjusts Price Target on Seres Therapeutics to $15 From $11, Maintains Buy Rating MT
09/03/23 Canaccord Genuity Lowers Price Target on Seres Therapeutics to $11 From $17, Maintains Buy Rating MT
07/09/22 Piper Sandler Adjusts Price Target on Seres Therapeutics to $9 From $7, Reiterates Overweight Rating MT
05/08/22 Chardan Capital Lowers Seres Therapeutics Price Target to $12 From $16, Maintains Buy Rating MT
04/08/22 Oppenheimer Adjusts Seres Therapeutics' Price Target to $12 From $13, Maintains Outperform Rating MT
24/05/22 Piper Sandler Lowers Seres Therapeutics' to $7 From $32, Overweight Rating Kept MT
03/03/22 Oppenheimer Adjusts Seres Therapeutics Price Target to $13 From $16, Maintains Outperform Rating MT
24/07/21 Seres Therapeutics : Oppenheimer Adjusts Seres Therapeutics PT to $18 From $36, Maintains Outperform Rating MT
24/07/21 Seres Therapeutics : Chardan Adjusts Price Target on Seres Therapeutics to $16 From $30 After Drug Disappoints in Study, Maintains Buy Rating MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
- +1,178.2%
+40.13%
+18.8%
+8.94%
+17.72%
+24.48%
+29.56%
+72.29%
+19.97%
+34.42%
Average +144.45%
Weighted average by Cap. +28.31%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.240USD
Average target price
17.00USD
Spread / Average Target
+1,270.97%
High Price Target
22.00USD
Spread / Highest target
+1,674.19%
Low Price Target
12.00USD
Spread / Lowest Target
+867.74%

Analyst Consensus Detail

Analyst consensus - Seres Therapeutics, Inc.

Consensus revision (last 18 months)

Consensus revision (last 18 months) - Seres Therapeutics, Inc.
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - Seres Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. MCRB Stock
  4. Consensus Seres Therapeutics, Inc.